CVC Capital and Groupe Bruxelles Lambert (GBL) Launch €10.7B Tender Offer to Take Recordati Private

Shots: A consortium led by CVC and GBL launched a voluntary cash tender offer to acquire Recordati at €51.29/share, valuing the transaction at ~€10.7B (~$12.4B). The offer aims to delist Recordati from Euronext Milan & is expected to close in Q4’26 The offer is backed by Rossini, which agreed to tender its 97.9M shares (~46.8%…

ByRidhi Rastogi1 day ago

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Shots: Recordati has received a non-binding indication of interest from CVC Capital Partners for a voluntary tender offer to acquire all outstanding shares & delist the company, subject to due diligence, financing, & partner identification Recordati expanded into rare diseases with its 2021 acquisition of EUSA Pharma for ~$845M, strengthening its rare cancer portfolio The…

ByRidhi RastogiMarch 31, 2026

Recordati and Moderna Collaborate To Develop And Commercialize mRNA 3927 in a ~$160M Deal

Shots: Recordati has entered into a collaboration & license deal with Moderna to develop & commercialize mRNA-3927 globally for the treatment of propionic acidemia As per the deal, Moderna will continue to co-develop mRNA-3927 with Recordati, while Recordati will lead global commercialization if approved. In exchange, Moderna will receive $50M upfront, ~$110M in development &…

ByRidhi RastogiJanuary 30, 2026

CVC Capital and Groupe Bruxelles Lambert (GBL) Launch €10.7B Tender Offer to Take Recordati Private

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Recordati and Moderna Collaborate To Develop And Commercialize mRNA 3927 in a ~$160M Deal

Contact US

FOLLOW US